Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThruvision Grp Regulatory News (THRU)

Share Price Information for Thruvision Grp (THRU)

Share Price is delayed by 15 minutes
Get Live Data
0.725    0.00 (0.00%)
Bid:
0.70
Ask:
0.75
Spread: 0.05 (7.143%)
Market Cap: £3.24m
THRU Live PriceLast checked at - London Stock Exchange

Intraday Thruvision Grp Share Chart

Year-end trading update

26 Apr 2024 07:00

RNS Number : 1066M
Thruvision Group PLC
26 April 2024
 

26 April 2024

Thruvision Group plc

 

Year-end trading update

 

Thruvision (AIM: THRU, "Thruvision" or the "Group"), the leading international provider of walk-through security technology, today publishes a trading update for the financial year ended 31 March 2024 ("FY24").

 

· Revenue is expected to be in the order of £7.8 million (FY23: £12.4 million), made up primarily by Entrance Security, new Customs agency sales and Retail Distribution.

· Adjusted gross margin* remained strong and improved to 53.0% (FY23: 51.5%).

· The revenue reduction can be attributed to the previously announced lack of further significant orders from US Customs and Border Protection (CBP) in FY24.

· Adjusting for the impact of this single customer, revenue growth was 85% to £7.6 million (FY23: £4.1 million) on a like-for-like basis, demonstrating strong broad-based growth in demand for our solutions.

· US Transportation Security Administration (TSA) has recently changed its policy to require increased security screening of aviation employees, which has led to a meaningful pick-up in sales enquiries which we expect to lead to new sales in FY25.

· Approximately 70% of revenue came from the Group's existing customer base, most of whom were upgrading to our WalkTHRU solution.

· Adjusted EBITDA loss* is expected to be in the region of £2.5 million (FY23: loss of £0.2 million), which is in line with market expectations.

· Cash balance on 31 March 2024 was £4.1 million (31 March 2023: £2.8 million). The Group has no debt.

 

Colin Evans, Chief Executive, commented:

 

"Almost all demand we are now experiencing is for our WalkTHRU technology where our latest AI-based image processing software is further strengthening our market leadership.

 

The very strong revenue growth we achieved from customers outside of US Customs and Border Protection (CBP) is encouraging. In particular, the worsening geopolitical climate resulted in very strong interest from the Entrance Security market, a trend we expect to see continue. The Group's multi-year CBP framework purchasing agreement remains in place for when Congressional funding support returns and recent policy changes are now driving demand from US Aviation.

 

The fact that we are, post COVID, once again operating in four distinct end markets underpins our confidence in our future growth and our expectation that we will reach profitability in the short-term."

 

 

 

 

 

 

 

For further information please contact:

 

Thruvision Group plc +44 (0)1235 425400

Colin Evans, Chief Executive

Victoria Balchin, Chief Financial Officer

 

Investec Investment Banking (NOMAD & Broker) +44 (0)20 7597 5970

Patrick Robb / James Rudd / Sebastian Lawrence

 

Meare Consulting +44 (0) 7990 858548

Adrian Duffield

 

About Thruvision (www.thruvision.com)

 

Thruvision is the leading developer, manufacturer and supplier of advanced AI-based walk-through security technology internationally. Its technology is deployed in more than 20 countries around the world by government and commercial organisations in a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using advanced AI-based detection algorithms.

The Group's offices are near Oxford and Washington DC.

 

* Adjusted EBITDA loss is defined as statutory operating loss before depreciation and amortisation, share based payments and impairment of intangible assets. Adjusted gross margin is defined as the statutory gross margin excluding production overheads.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSELFMIELSEFL
Date   Source Headline
14th May 20267:00 amRNS-RNew Strategic Partnerships
7th May 202611:45 amRNSBlocklisting cancellation and interim review
7th May 202611:45 amRNSBlocklisting cancellation and interim review
8th Apr 20267:00 amRNSFY26 Trading Update
13th Mar 20267:00 amRNSUS Aviation Contract Award
13th Mar 20267:00 amRNSUS Aviation Contract Award
19th Feb 20267:00 amRNSHolding(s) in Company
19th Feb 20267:00 amRNSContract awards into UK custodial facilities
12th Feb 20267:00 amRNS-RFirst UK “Screening as a Service” Sales
22nd Jan 20267:00 amRNS-RUK Retail Distribution Contract Award
20th Jan 20267:00 amRNSSouth-East Asian Mass Transit Contract Award
12th Jan 20267:00 amRNSHolding(s) in Company
5th Jan 202611:27 amRNSAward of Share Options
19th Dec 20251:07 pmRNS-RUS Retail Distribution Contract Award
19th Dec 20251:07 pmRNS-RUS Retail Distribution Contract Award
16th Dec 20257:00 amRNSHolding(s) in Company
11th Dec 20257:00 amRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RImminent contract award
4th Dec 20257:00 amRNSHolding(s) in Company
28th Nov 20253:45 pmRNSHolding(s) in Company
26th Nov 20257:00 amRNSHolding(s) in Company
25th Nov 20257:00 amRNSInterim Results and Trading Update
6th Nov 20254:30 pmRNSBlock listing Interim Review
6th Nov 20254:30 pmRNSBlock listing Interim Review
23rd Oct 202510:53 amRNSResult of AGM
23rd Oct 20257:00 amRNSAGM Statement and Trading Update
6th Oct 20251:49 pmRNS-RNPSA Testing Update
30th Sep 202512:33 pmRNSHolding(s) in Company
29th Sep 202512:04 pmRNSHolding(s) in Company
29th Sep 202511:26 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSNotice of AGM
19th Sep 20257:00 amRNSFinal Results
15th Sep 202512:40 pmRNSHolding(s) in Company
9th Sep 20257:00 amRNS-RAdditions to Value-Added Reseller Network
1st Aug 20259:46 amRNSHolding(s) in Company
1st Aug 20257:00 amRNSHolding(s) in Company
31st Jul 20255:00 pmRNSTotal Voting Rights
31st Jul 20252:37 pmRNSHolding(s) in Company
31st Jul 20252:01 pmRNSHolding(s) in Company
31st Jul 202510:32 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHolding(s) in Company
29th Jul 20251:54 pmRNSHolding(s) in Company
28th Jul 202510:50 amRNSResult of GM and completion of Capital Raising
28th Jul 20257:00 amRNSChange of Adviser
8th Jul 20257:00 amRNSResult of Retail Offer & Notice of General Meeting
4th Jul 20257:05 amRNSWRAP Retail Offer
4th Jul 20257:00 amRNSResult of Review & Proposed Capital Raise
2nd Jul 20257:00 amRNSMaterial Contract Award and Trading Update
23rd Jun 20251:50 pmRNSHolding(s) in Company
23rd Jun 20257:00 amRNSUpdate on Strategic Review and Formal Sale Process

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.